Trade Summary

5 days ago, Collins Helen Louise, serving as Chief Medical Officer at Enliven Therapeutics, Inc. (ELVN), sold 45,000 shares at $26.17 per share, for a total transaction value of $1,177,862.00. Following this transaction, Collins Helen Louise now holds 25,000 shares of ELVN.

This sale represents a 64.00% decrease in Collins Helen Louise's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Tuesday, February 17, 2026 and publicly disclosed via SEC Form 4 filing on Thursday, February 19, 2026, 2 days after the trade was made.

Enliven Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.